371 related articles for article (PubMed ID: 19392858)
1. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
[TBL] [Abstract][Full Text] [Related]
2. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
3. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
5. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
Pearce CB; Lawrance IC
J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
[TBL] [Abstract][Full Text] [Related]
6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
7. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
9. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
10. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
11. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
[TBL] [Abstract][Full Text] [Related]
12. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
13. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
15. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
16. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
17. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
[TBL] [Abstract][Full Text] [Related]
18. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ
Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273
[TBL] [Abstract][Full Text] [Related]
19. [Optimizing effect of infliximab upon inflammatory bowel disease].
Li SR; Sheng JQ; Li SJ; Zhao XJ
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
[TBL] [Abstract][Full Text] [Related]
20. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
